Twist Bioscience (TWST) announced the appointment of Adam Laponis as chief financial officer. Laponis brings experience across small cap and Fortune 50 companies along with a track record of collaborating across teams to drive profitable growth. Laponis joins Twist from Eargo (EAR), where he served as chief financial officer, responsible for finance, accounting, investor relations, business operations, internal audit and information technology.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TWST:
- Twist Bioscience named a best idea for 2024 at TD Cowen
- Twist Bioscience price target raised to $30 from $26 at Barclays
- Twist Bioscience price target raised to $32 from $26 at Evercore ISI
- Twist Bioscience sees FY24 revenue $285M-$290M, consensus $298.67M
- Twist Bioscience sees Q1 revenue $67M-$68M, consensus $63.45M
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue